On September 25, 2020, Aimed Alliance asked New York assembly members to support the passage of A8246, a bill that would limit health insurers’ use of copay accumulator programs. In particular, A8246 prohibits health insurers from adopting copay accumulator programs for a branded drug unless a medically appropriate generic medication is available. The bill is crafted to incentivize patients to use lower cost medications only when such medications are available and deemed medically appropriate, but it recognizes that copay accumulator programs are inappropriate where no generic alternative exists. As such, A8246 strikes a balance between the interests of health plans and pharmaceutical manufacturers without unreasonably penalizing patients for relying on financial assistance. Our letter is available here.